Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
ACWF President Stresses the Role of Women, Women's Federations in COVIDACWF and Supreme People's Procuratorate Join Hands to Strengthen Protection of Women and ChildrenFrom masterpiece to marketplace, creative museum souvenirs go viral among Chinese youthACWF Releases Posters to Publicize AntiACWF Releases Q&A ENational ParentACWF Calls on Women, Families to Stop Wasting Food, Promote Thrifty LivingFrom masterpiece to marketplace, creative museum souvenirs go viral among Chinese youthMore Foreign Women's Organizations and Overseas Chinese Support China in Battle Against NCPACWF Releases Posters to Publicize Anti
3.0387s , 4667.3359375 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Stellar Stories news portal